Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer
Tamar Zahavi, Mali Salmon-Divon, Roberto Salgado, Michael Elkin, Esther Hermano, Ariel M Rubinstein, Prudence A Francis, Angelo Di Leo, Giuseppe Viale, Evandro de Azambuja, Lieveke Ameye, Christos Sotiriou, Asher Salmon, Nataly Kravchenko-Balasha, Amir Sonnenblick
NPJ BREAST CANCER | NATURE RESEARCH | Published : 2021
Heparanase promotes tumor growth in breast tumors. We now evaluated heparanase protein and gene-expression status and investigated its impact on disease-free survival in order to gain better insight into the role of heparanase in ER-positive (ER+) breast cancer prognosis and to clarify its role in cell survival following chemotherapy. Using pooled analysis of gene-expression data, we found that heparanase was associated with a worse prognosis in estrogen receptor-positive (ER+) tumors (log-rank p < 10-10) and predictive to chemotherapy resistance (interaction p = 0.0001) but not hormonal therapy (Interaction p = 0.62). These results were confirmed by analysis of data from a phase III, prospe..View full abstract
Awarded by Clinical Research Career Development Award from the Israel Cancer Research Fund grants
Awarded by Israeli cancer research association
A.S. is supported by a Clinical Research Career Development Award from the Israel Cancer Research Fund grants (16-116-CRCDA) and from the Israeli cancer research association (2017-0140). A.S. was an ESMO translational research fellow.